SHORT MINI FUTURE - MODERNA | Market Closed - Swiss Exchange 16:20:00 30/05/2024 BST | ||
| 1.67 CHF | -1.18% |
|
| Current month | -26.43% | ||
| 1 month | -26.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 30/05/24 | 1.67 | -1.18% |
| 29/05/24 | 1.69 | +11.18% |
| 28/05/24 | 1.52 | +18.75% |
| 27/05/24 | 1.28 | -0.78% |
| 24/05/24 | 1.29 | -4.44% |
Delayed Quote Swiss Exchange
Last update May 30, 2024 at 04:20 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| LMRNJB | |
| ISIN | CH1242784218 |
| Date issued | 19/01/2023 |
| Strike | 235 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | CHF |
Technical Indicators
| Highest since issue | 2.99 CHF |
|---|---|
| Lowest since issue | 0.65 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.60% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
151.5
USD
Average target price
138.8
USD
Spread / Average Target
-8.39%
- Stock Market
- Certificates
- LMRNJB Certificat
